Momenta to reduce its biosimilars programmes

Home/Pharma News | Posted 26/10/2018 post-comment0 Post your comment

US-based biotechnology firm Momenta Pharmaceuticals (Momenta) announced on 1 October 2018 that it would be focusing on two key biosimilars and quit the development of five others.


The company says that it will be focusing on its two late-stage biosimilar assets. These include its wholly-owned candidate adalimumab biosimilar, M923; and M710, its candidate aflibercept biosimilar which is being developed in collaboration with Mylan.

Momenta made a deal with US generics giant Mylan back in 2016 for six biosimilars, which included a candidate abatacept biosimilar, M834, as well as the candidate aflibercept biosimilar, M710 [1]. However, the company now says that it ‘has initiated discussions’ with Mylan ‘to exit its participation in the development of its other five biosimilar program[me]s including M834’.

The decision says Momenta is ‘aimed at reducing costs of biosimilar development and focusing the company’s resources on its pipeline of novel drug candidates for immune-mediated diseases’.

Momenta and Mylan are currently carrying out a phase III trial for M710 in subjects with diabetic macular oedema [2]. Momenta also reported positive results from a phase III trial of M923 in November 2016 [3].

Related articles
Biosimilars of aflibercept

Baxalta and Momenta part ways on adalimumab biosimilar

Biosimilars of abatacept

1. GaBI Online - Generics and Biosimilars Initiative. Mylan and Momenta to jointly develop and commercialize six biosimilar products []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Oct 26]. Available from:
2. GaBI Online - Generics and Biosimilars Initiative. Mylan/Momenta announce development strategy for aflibercept biosimilar []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Oct 26]. Available from:
3. GaBI Online - Generics and Biosimilars Initiative. Positive phase III results for adalimumab and trastuzumab biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Oct 26]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Momenta

comment icon Comments (0)
Post your comment
Related content
Licensing agreements signed for ustekinumab biosimilars
Home/Pharma News Posted 17/09/2021
Oncogen–BrightGene partnership
104 MD001918
Home/Pharma News Posted 10/09/2021
Menagen–CKD Middle Eastern partnership
01 AA007239
Home/Pharma News Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010